“Everything that’s good for patients delivers extraordinary value for biopharma - that overlap is the entire company,” says Shashi Shankar, CEO. From symptom tracking to AI-driven normalization, Novellia builds patient-first data infrastructure that scales into biopharma-grade intelligence. Since we last spoke, could you give us an overview of how
An interview with Dr. Bharat Sangani Trust isn’t optional — it’s the foundation: Unlike many data companies that operate in the shadows, we’ve built Novellia on explicit patient consent and control. Every patient actively chooses whether to contribute their anonymized data to specific research initiatives. That transparency turns
FirstWord HealthTech’s ViewPoints feature explores how Novellia’s AI-enabled health data platform is powering Project EVEREST, a bold, cross-industry initiative to address disparities in breast cancer treatment. Despite well-established breast cancer treatment guidelines, adherence remains inconsistent, especially in community settings. Backed by top-tier research institutions and leading biopharma companies
Award recognizes leaders using AI to expand equity and reshape access to care NEW YORK, June 12, 2025 – Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced that its CEO and co-founder Shashi Shankar has been named
First-of-its-kind quality improvement initiative, Project EVEREST, is backed by Daiichi Sankyo, Genentech, and AstraZeneca. NEW YORK, May 28, 2025 – Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced the launch of Project EVEREST—a groundbreaking, cross-industry initiative
Prestigious awards program honors Novellia’s AI-enabled platform for transforming fragmented health records into real-world research breakthroughs NEW YORK, – May 8, 2025 – Novellia, Inc., an AI-enabled personal health data company redefining how real-world evidence is generated, today announced it has been named the winner of the “Best Electronic Health Record
Shashi Shankar explains how his app unifies patients' scattered medical records all together, and what that has to do with the 21st Century Cures Act. Onyx By Dr. Adil Ali March 20, 2025 Shashi Shankar, CEO of Novellia, sat down with Onyx for a feature-length interview. Could you explain
NEW YORK, Feb. 11, 2025 – Novellia, Inc., an AI-enabled health data company harnessing the power of personal healthcare data to drive precision medicine forward, is pleased to announce its recognition as one of Digital Health New York's 10 Startups to Watch for 2025, underscoring the impact of Novellia&
-New research demonstrates integrating AI-enabled, health record data insights with targeted educational interventions can enhance understanding and management of serious adverse events, such as interstitial lung disease (ILD), in real-world settings -Project EVOLVE, funded by Daiichi Sankyo and AstraZeneca, to be presented at the 2024 San Antonio Breast Cancer Symposium
-Research study presented at the 2024 ASCO Quality Care Symposium uses Novellia's AI-enabled technology and personal health record platform to unlock insights that can inform patient care NEW YORK, September 30, 2024 -- Novellia, Inc., an AI-enabled personal health data company dedicated to bridging the gap between real-world
NEW YORK, NY, November 6, 2023 - Novellia, Inc., an AI-enabled health data company harnessing the power of personal healthcare to drive precision medicine forward, announces the initiation of its second major digital health record registry solution, this time focusing on non-small cell lung cancer (NSCLC) biomarker testing at the
NEW YORK, NY, August 7, 2023 - Novellia, Inc., an AI-enabled health data company harnessing the power of personal healthcare to drive precision medicine forward, announces the launch of Project EVOLVE using its custom digital registry solution for tracking real-world outcomes in HER2+ breast cancer treatment. Project EVOLVE, funded by